Testosterone (Research) – Kodiac biolabs

Plain-language summaryIntrigue 75 / 100

Testosterone is the principal androgen in humans, made from cholesterol in the testes (men) and ovaries plus adrenals (women). It is the foundational compound of androgen pharmacology and the active ingredient in essentially all testosterone replacement therapy plus the backbone of most non-medical anabolic steroid stacks. It binds the androgen receptor directly and is also converted on the fly into dihydrotestosterone (more potent androgen) by 5-alpha-reductase, and into estradiol by aromatase. Sold as cypionate, enanthate, propionate, undecanoate, plus gels and patches, with each ester releasing testosterone over different timescales. Schedule III in the US. The reference androgen receptor agonist for nearly all related research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

44/100

Canonical AR reference compound; foundational but thoroughly mapped, with frontier interest squarely elsewhere

Look, testosterone occupies a genuinely strange position in any research library. It’s the foundational androgen – first isolated by David, Dingemanse, Freud, and Laqueur in 1935, structure confirmed by Butenandt and Ruzicka (Nobel, 1939), and under continuous clinical deployment ever since. At this point, the AR pharmacology is about as well-characterized as receptor biology gets. Ki of roughly 0.5 nM at AR, 5-alpha-reductase conversion to the more potent DHT, aromatase conversion to estradiol. We know this chemistry cold. Thats not a criticism; its just the reality of a compound that has been under rigorous investigation for ninety years across thousands of labs.

The mechanism doesn’t earn novelty points here. Single-receptor agonism in the most saturated steroid class in pharmacology. The interesting research questions around androgen biology, tissue selectivity, AR coactivator recruitment, non-genomic signaling pathways: those are now answered more cleanly with SARMs and selective AR modulators designed specifically to probe those dimensions. If you want to study differential anabolic-to-androgenic ratios, LGD-4033 or RAD-140 are sharper instruments. If you want AR pathway studies without aromatization confound, you need to block aromatase anyway. Testosterone does AR agonism and aromatization simultaneously, which is a physiological feature but a research design confounder.

What actually scores well here is evidence quality and translational signal, and those scores are real. FDA approval for hypogonadism across multiple ester formulations (cypionate, enanthate, propionate, undecanoate). Decades of replicated RCTs, well-characterized PK across routes of administration, solid safety profiling across hematocrit, lipid, and hormonal endpoints. If you’re building a disease model around male hypogonadism or studying androgen-mediated muscle protein synthesis in a clinical context, this is your reference compound, full stop.

Where we find genuine bench value is specifically in the reference probe role. AR binding competition assays, androgen-responsive cell line studies (LNCaP, LAPC4), steroidogenesis pathway models, castration-and-replacement designs in rodents: testosterone is the canonical standard against which everything else is calibrated. That role keeps the bench value score from collapsing. But it’s not a compound you reach for because you’re curious about what it does. You reach for it because you need to establish what something else does relative to it.

Honestly, the overall score here reflects one simple fact: testosterone is so thoroughly understood that the primary research questions it can answer are mostly already answered. The frontier in androgen biology has moved to selective modulators, non-steroidal AR ligands, the androgen receptor splice variants driving castration-resistant prostate cancer, and the complex crosstalk between androgen signaling and metabolic pathways. Testosterone stays in the library as a reference standard and clinical backbone. As an object of primary investigation in 2026, its not where serious investigators are finding new ground.

Novelty: 10
Mechanism promise: 20
In-category differentiation: 42
Evidence quality: 80
Translational signal: 74
Research bench value: 68

Rationale Testosterone scores high on evidence quality and translational signal (FDA-approved, multi-decade RCT base) but bottoms out on novelty and mechanism promise; it’s the prototype AR agonist in the most saturated steroid pharmacology class in existence, and the live research questions in androgen biology are now prosecuted more precisely with SARMs and selective probes. The Schedule III cap (75) does not bind because the weighted score lands well below it.

Endogenous androgen / anabolic-androgenic steroid

The principal endogenous androgen; the foundational compound of androgen pharmacology and the active component of TRT and many AAS regimens.

Abstract

Testosterone (17-beta-hydroxyandrost-4-en-3-one; CAS 58-22-0; molecular formula C19H28O2; molecular weight 288.42) is the principal endogenous androgen, biosynthesized from cholesterol via pregnenolone and progesterone in Leydig cells of the testis (males) and theca cells, ovary, and adrenal cortex (females). The compound is the prototype androgen receptor agonist and the foundation of androgen pharmacology. Pharmacologically, testosterone binds AR (Ki approximately 0.5 nM) and is converted to dihydrotestosterone (DHT) by 5-alpha-reductase (more potent AR agonist) and to estradiol by aromatase (estrogen receptor agonist). Approved as testosterone replacement therapy in male hypogonadism via various ester formulations: cypionate (weekly), enanthate (weekly), propionate (every 2 to 3 days), undecanoate (oral and depot), gels and patches (daily). Schedule III in the US under the CSA. The compound is the foundation of most anabolic-androgenic steroid (AAS) regimens used non-medically for muscle building. Plasma half-life of native testosterone is short (1 to 2 hours); ester formulations release the parent compound over days. Used as the canonical AR agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-386Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.